Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts. On ...

The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.

The consumer privacy ombudsman in 23andMe’s sale of customers’ genetic data is defending his choice of counsel against ...

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some ...

Analysts expect the S&P 500 to rise 7.5% over the next year, according to a recent analysis of stock price targets. Wall Street thinks these companies have the most upside and downside potential.

Fujifilm’s Life Sciences Group is renaming two of its companies, in a rebranding intended to position parent company Fujifilm as a strategic partner.

See the latest Regeneron Pharmaceuticals Inc stock price (REGN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Review the current Regeneron Pharmaceuticals Inc (REGN:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if REGN is the best investment for you.